Results from the first Phase III trial in obesity and overweight investigating the GIPR/GLP-1R co-agonist tirzepatide, which is currently approved for the treatment of type 2 diabetes and has resulted in marked body-weight reductions in type 2 diabetes [5, 43,44,45,46], were published in 2022 [28]
Researchers selecting a compound for a specific endpoint should match mechanism to model rather than treating these peptides as interchangeable
California Trim Clinic works with licensed pharmacy partners and does not source research-grade, gray-market, or black-market peptide products
Each fast-dissolving tablet delivers 100 mg of reduced glutathione directly through the sublingual mucosa, bypassing the liver for superior absorption and faster results
Over 64% of people without diabetes and nearly 47% of those with diabetes stopped GLP-1 therapy within a year